Emerging from a crisis in anticancer drug discovery? Screening versus design: confessions of an optimistic fence-sitter

Correction: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.

Oncogene·2020

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

Blood cancer journal·2017

A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset.

Psychological medicine·2016

Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins.

Oncogene·2013

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.

British journal of cancer·2013

Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.

Clinical pharmacology and therapeutics·2013

Prospective circulating tumour DNA surveillance in patients with early high-risk hormone receptor positive, HER2-negative breast cancer in the TRAK-ER study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Final Analysis of the Neotorch Study: Perioperative Toripalimab in Combination with Chemotherapy for Patients with Stage Ⅱ/Ⅲ Resectable Non-Small Cell Lung Cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: final overall survival analysis of the Phase III OptiTROP-Breast01.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Efficacy and safety of risvutatug rezetecan versus gemcitabine plus docetaxel in relapsed/refractory advanced osteosarcoma: Primary results from the ARTEMIS-011 phase 3 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase III DeLLphi-304 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 Trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

G-quadruplex ligand-mediated CHK1 and ERα suppression in endocrine-sensitive and endocrine-resistant luminal breast cancer cells.

Cell cycle (Georgetown, Tex.)·2026

Obeticholic acid: discovery, clinical translation, and regulatory withdrawal.

European review for medical and pharmacological sciences·2026

An Act of DeFianCe: Targeting DKK1 in Metastatic Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

An Orthotopic Xenograft Model for Preclinical Evaluation of CAR T Cell Therapy in Glioblastoma.

Current protocols·2026

Cardiac toxicity and dysrhythmias in acute poisoning: a ten-year cohort study.

Clinical toxicology (Philadelphia, Pa.)·2026

Anticancer activity and ADME-toxicity evaluation of novel synthesized chalcone-sulfonate derivatives in osteosarcoma cells and the effect of electroporation.

Future medicinal chemistry·2026

Emerging from a crisis in anticancer drug discovery? Screening versus design: confessions of an optimistic fence-sitter

Related Experiment Videos

Related Concept Videos

Correction: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset.

Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins.

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.

Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.

Prospective circulating tumour DNA surveillance in patients with early high-risk hormone receptor positive, HER2-negative breast cancer in the TRAK-ER study.

Final Analysis of the Neotorch Study: Perioperative Toripalimab in Combination with Chemotherapy for Patients with Stage Ⅱ/Ⅲ Resectable Non-Small Cell Lung Cancer.

Sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: final overall survival analysis of the Phase III OptiTROP-Breast01.

Efficacy and safety of risvutatug rezetecan versus gemcitabine plus docetaxel in relapsed/refractory advanced osteosarcoma: Primary results from the ARTEMIS-011 phase 3 trial.

Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase III DeLLphi-304 study.

Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 Trial.

G-quadruplex ligand-mediated CHK1 and ERα suppression in endocrine-sensitive and endocrine-resistant luminal breast cancer cells.

Obeticholic acid: discovery, clinical translation, and regulatory withdrawal.

An Act of DeFianCe: Targeting DKK1 in Metastatic Colorectal Cancer.

An Orthotopic Xenograft Model for Preclinical Evaluation of CAR T Cell Therapy in Glioblastoma.

Cardiac toxicity and dysrhythmias in acute poisoning: a ten-year cohort study.

Anticancer activity and ADME-toxicity evaluation of novel synthesized chalcone-sulfonate derivatives in osteosarcoma cells and the effect of electroporation.

Emerging from a crisis in anticancer drug discovery? Screening versus design: confessions of an optimistic fence-sitter

Related Experiment Videos

Related Concept Videos

Related Articles